Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis

Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes

(2015) James E. Tooley et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

(2015) Mark R. Rigby et al.   JOURNAL OF CLINICAL INVESTIGATION

Thinking bedside at the bench: the NOD mouse model of T1DM

(2015) James C. Reed et al.   Nature Reviews Endocrinology

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

(2013) K. C. Herold et al.   DIABETES

Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes: Two-Year Results From the Randomized, Placebo-Controlled Protege Trial

(2013) W. Hagopian et al.   DIABETES

B-Lymphocyte Depletion With Rituximab and  -Cell Function: Two-Year Results

(2013) M. D. Pescovitz et al.   DIABETES CARE

Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment

(2013) Tihamer Orban et al.   DIABETES CARE

Characterization of residualβcell function in long-standing type 1 diabetes

(2013) Jennifer L. Sherr et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial

(2012) K. C. Herold et al.   DIABETOLOGIA

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

(2011) Nicole Sherry et al.   LANCET

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

(2010) B. Keymeulen et al.   DIABETOLOGIA

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

(2009) Mark D. Pescovitz et al.   NEW ENGLAND JOURNAL OF MEDICINE